Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Clinical-trials-phase-iii crawled date : 2022 - 05 - 03 save search
LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data from Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Published: 2022-05-03 (Crawled : 19:00) - biospace.com/
LIAN | $4.92 0.41% 0.41% 410K
|
Professional, Scientific, and T...
|
| O: -2.43%
H: 5.25%
C: -12.98%
TARS | $33.63 -2.3% 57K
|
Health Technology
|
| O: -0.79%
H: 0.36%
C: -6.05%
tp-03 treatment topline trial positive
PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: -1.04%
H: 14.36%
C: 3.87%
skinte drug diabetic enroll
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Published: 2022-05-03 (Crawled : 12:20) - biospace.com/
BTAI | $2.58 -0.39% 110K
|
Health Technology
|
| O: 4.1%
H: 1.65%
C: 1.01%
treatment disease trial therapeutics alzheimer’s phase 3 alzheimer's
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
RVPH | $3.14 -1.88% 37K
|
|
| O: -8.29%
H: 14.69%
C: 10.17%
treatment brilaroxazine schizophrenia phase 3
Gainers vs Losers
| 81% | 19% |
Top 10 Gainers
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
XPON | $2.66 37.82% 5.2M
|
SINT | $0.0504 35.12% 300M
|
Health Technology
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
MLEC | $1.8 27.66% 2.1M
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.